ABILIFY by Otsuka is unknown. First approved in 2006.
Drug data last refreshed 20h ago
unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Specified Drug-use Survey on Abilify Prolonged Release Aqueous Suspension for IM Injection (Prevention of Relapse of Mood Episodes in BP)
A Trial in Adult Participants With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®
A Trial to Measure the Difference in All-cause Hospitalizations for Participants Who Are Using Abilify MyCite Versus Virtual Matched Controls in Adults With Schizophrenia, Bipolar 1 Disorder, and Major Depressive Disorder
A Study of Abilify® Tablet(Aripiprazole) as an Adjunctive Treatment in the Bipolar Depression
Bioequivalence Study of Bosiqing and ABILIFY Under Fasting/Fed Condition
Worked on ABILIFY at Otsuka? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moPatent cliff in less than a year — expect lifecycle management and generic defense hiring